{"id":3596,"date":"2024-05-23T21:39:04","date_gmt":"2024-05-23T13:39:04","guid":{"rendered":"https:\/\/flcube.com\/?p=3596"},"modified":"2024-10-21T18:30:07","modified_gmt":"2024-10-21T10:30:07","slug":"milliporesigma-avoids-prosecution-in-biochemical-diversion-case-a-doj-first","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=3596","title":{"rendered":"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First"},"content":{"rendered":"\n

Merck KGaA (NYSE: MRK<\/a>)’s US life sciences division, MilliporeSigma, has been at the center of a US Department of Justice (DoJ) investigation into the fraudulent sale and export of biochemicals, including cocaine and fentanyl, to China. The scheme, which lasted from July 2016 until its discovery in May 2023, involved two individuals: Gregory Mu\u00f1oz, a salesperson for MilliporeSigma, and Pen (Ben) Yu. Yu, posing as a university research lab employee, secured significant discounts on approximately $14 million worth of biochemicals, with nearly $5 million in discounts facilitated by Mu\u00f1oz. The DoJ has declined to press charges against MilliporeSigma due to the company’s swift self-reporting and cooperation.<\/p>\n\n\n\n

The seven-year conspiracy saw Yu and Mu\u00f1oz engage in wire fraud, using gift cards as compensation and falsifying export documents to ship the chemicals to China. Both have pleaded guilty to wire fraud conspiracy and are awaiting sentencing. This case marks the first time the DoJ’s National Security Division has declined prosecution of a company under its voluntary self-disclosure program, highlighting the importance of corporate compliance and transparency.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Merck KGaA (NYSE: MRK)’s US life sciences division, MilliporeSigma, has been at the center of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[120,750,903],"class_list":["post-3596","post","type-post","status-publish","format-standard","hentry","category-company","category-legal-ip","tag-merck","tag-milliporesigma","tag-nyse-mrk"],"yoast_head":"\nMilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA's US life sciences division, MilliporeSigma, has been at the center of a US Department of Justice (DoJ) investigation into the fraudulent sale and export of biochemicals, including cocaine and fentanyl, to China. The scheme, which lasted from July 2016 until its discovery in May 2023, involved two individuals: Gregory Mu\u00f1oz, a salesperson for MilliporeSigma, and Pen (Ben) Yu. Yu, posing as a university research lab employee, secured significant discounts on approximately $14 million worth of biochemicals, with nearly $5 million in discounts facilitated by Mu\u00f1oz. The DoJ has declined to press charges against MilliporeSigma due to the company's swift self-reporting and cooperation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=3596\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=3596\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-23T13:39:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-21T10:30:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3596#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3596\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First\",\"datePublished\":\"2024-05-23T13:39:04+00:00\",\"dateModified\":\"2024-10-21T10:30:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3596\"},\"wordCount\":189,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Merck\",\"MilliporeSigma\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3596#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3596\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=3596\",\"name\":\"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-05-23T13:39:04+00:00\",\"dateModified\":\"2024-10-21T10:30:07+00:00\",\"description\":\"Merck KGaA's US life sciences division, MilliporeSigma, has been at the center of a US Department of Justice (DoJ) investigation into the fraudulent sale and export of biochemicals, including cocaine and fentanyl, to China. The scheme, which lasted from July 2016 until its discovery in May 2023, involved two individuals: Gregory Mu\u00f1oz, a salesperson for MilliporeSigma, and Pen (Ben) Yu. Yu, posing as a university research lab employee, secured significant discounts on approximately $14 million worth of biochemicals, with nearly $5 million in discounts facilitated by Mu\u00f1oz. The DoJ has declined to press charges against MilliporeSigma due to the company's swift self-reporting and cooperation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3596#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3596\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3596#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First - Insight, China's Pharmaceutical Industry","description":"Merck KGaA's US life sciences division, MilliporeSigma, has been at the center of a US Department of Justice (DoJ) investigation into the fraudulent sale and export of biochemicals, including cocaine and fentanyl, to China. The scheme, which lasted from July 2016 until its discovery in May 2023, involved two individuals: Gregory Mu\u00f1oz, a salesperson for MilliporeSigma, and Pen (Ben) Yu. Yu, posing as a university research lab employee, secured significant discounts on approximately $14 million worth of biochemicals, with nearly $5 million in discounts facilitated by Mu\u00f1oz. The DoJ has declined to press charges against MilliporeSigma due to the company's swift self-reporting and cooperation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=3596","og_locale":"en_US","og_type":"article","og_title":"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=3596","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-05-23T13:39:04+00:00","article_modified_time":"2024-10-21T10:30:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=3596#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=3596"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First","datePublished":"2024-05-23T13:39:04+00:00","dateModified":"2024-10-21T10:30:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=3596"},"wordCount":189,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Merck","MilliporeSigma","NYSE: MRK"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=3596#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=3596","url":"https:\/\/flcube.com\/?p=3596","name":"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-05-23T13:39:04+00:00","dateModified":"2024-10-21T10:30:07+00:00","description":"Merck KGaA's US life sciences division, MilliporeSigma, has been at the center of a US Department of Justice (DoJ) investigation into the fraudulent sale and export of biochemicals, including cocaine and fentanyl, to China. The scheme, which lasted from July 2016 until its discovery in May 2023, involved two individuals: Gregory Mu\u00f1oz, a salesperson for MilliporeSigma, and Pen (Ben) Yu. Yu, posing as a university research lab employee, secured significant discounts on approximately $14 million worth of biochemicals, with nearly $5 million in discounts facilitated by Mu\u00f1oz. The DoJ has declined to press charges against MilliporeSigma due to the company's swift self-reporting and cooperation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=3596#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=3596"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=3596#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3596"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3596\/revisions"}],"predecessor-version":[{"id":8441,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3596\/revisions\/8441"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}